Pharma: Other News To Note

• Baxter International Inc., of Deerfield, Ill., said it submitted a biologics license application for approval of BAX 326, a recombinant Factor IX protein, for the treatment and prophylaxis of bleeding episodes for patients older than 12 with hemophilia B.